Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients
Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients is a paper indexed in PICO Portal from OpenAlex.
How many citations does Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients have?
Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients has 113 citations in the OpenAlex counts PICO Portal stores.
When was Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients published?
Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients has 2003 year in the PICO Portal index.
What is the open-access status of Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients?
Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients has closed oa status in the PICO Portal index.
What is the DOI of Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients?
The DOI for Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients is on the source record.
What is the PMID of Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients?
The PMID for Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients is on the source record.
What is the OpenAlex record for Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients?
The OpenAlex for Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients is on the source record.